Niederer Kraft Frey advised TEC Group Swiss, backed by Sienna Private Equity, on the acquisition of Transcendance, a watchmaking decoration specialist — marking the group’s second build-up acquisition since its private equity partnership began.
Swiss law firm MME has advised Healthcare Holding Schweiz on the acquisition of Compet Medical, a harm reduction product supplier with over three decades of experience serving public institutions and healthcare professionals.
Homburger advised Siegfried Holding on the issuance of its CHF 200 million 1.350% bonds. UBS Investment Bank and Zürcher Kantonalbank acted as joint lead managers. The bonds will be issued on June 15, 2026, and will be listed
Homburger advised Idorsia, as the Six-listed commercial-stage biopharmaceutical company entered into a senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors. The first tranche of CHF 150 million
MME has advised KIBAG on its acquisition of Grob Kies in Toggenburg, Switzerland. The transaction is expected to close in July 2026.
Hombuerger advised Six-listed Temenos (SIX: TEMN), a specialist in banking technology, on its acquisition of Additiv, a Swiss fintech company providing a platform to orchestrate financial services. The transaction is subject to customary closing conditions.
Walder Wyss advised the shareholders of Ferax Treuhand as the state-supervised fiduciary and audit firm based in Zurich, and focused on audit services for the insurance sector has entered into a strategic partnership with Trusso
Baer & Karrer advised Trusso Group on its strategic partnership with Ferax Treuhand, a Zurich-based audit and accounting firm specialising in the insurance sector.
CMS Switzerland advised Rentokil Initial in connection with the acquisition of Zurich-based Hydroplant. The transaction was completed on 31 March 2026. The parties Hydroplant is a specialised provider of custom interior and exterior greening solutions, designing and
Eli Lilly agreed to acquire LimmaTech Biologics — a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases — for up to USD 780 m in cash, inclusive of an upfront payment and additional potential
